Wara Samar
2nd July 2025
Senior Lecturer Dr Haider Raza Joins Check4Cancer’s Clinical Advisory Board to Support AI Skin Cancer Model
On 1 July 2025, Check4Cancer officially welcomed Dr Haider Raza to its Clinical Advisory Board, a move that signals the company’s deepening commitment to responsible and effective use of AI in early cancer detection. Dr Raza, a Senior Lecturer at the University of Essex, will play a key role in guiding the development and deployment of Check4Cancer’s skin cancer AI model in the UK and internationally.
Dr Raza isn’t a new face to the company. He was a key member of the Innovate UK-funded Knowledge Transfer Partnership (KTP) team that helped design and build the AI model now at the heart of Check4Cancer’s approach to skin cancer triage. His background in machine learning, computational intelligence, and public health analytics has long focused on real-world applications—including his work developing an AI-assisted decision-making system for NHS cancer pathways in Essex.
Putting AI to Work in Clinical Settings
Check4Cancer has carved out a distinct position in the UK cancer diagnostics space by focusing on quick, accessible screening services for some of the most common and treatable cancers. Skin cancer, in particular, has been a natural candidate for AI support, with the potential to reduce unnecessary referrals and catch warning signs earlier. But while the promise of AI in dermatology is well-publicised, turning that promise into safe and trustworthy tools is another matter.
By bringing Dr Raza into a formal advisory role, the company is hoping to bridge the often-cited gap between AI development and clinical deployment. In his new position, Dr Raza will support Check4Cancer’s expanding data science team and advise the Board on AI adoption strategies, with a strong emphasis on model safety, reliability, and explainability.
“We are delighted that Dr Raza has agreed to join the Check4Cancer team as an AI advisor,” said Professor Gordon Wishart, Chief Medical Officer and CEO at Check4Cancer. “He was instrumental in developing our skin cancer AI model and he will now help us deliver improved patient care by ensuring that our AI model is safe, reliable and explainable.”
Also Read: MedTech World Bay Area 2025 Drew 100 Startups & 150 Investors to San Jose
That focus on explainability is not just a technical concern—it’s a necessity. As clinicians face increasing pressure to integrate digital tools into everyday workflows, trust in AI recommendations is paramount. Models that function as “black boxes” are unlikely to gain traction in real-world healthcare environments. Dr Raza’s research has consistently aimed to make AI systems more transparent and clinically interpretable.
As of this month, his involvement with Check4Cancer will move from the collaborative to the strategic. With him advising at the Board level, the company is doubling down on its ambition to offer AI tools that are not only scientifically sound, but also usable and trusted in primary care settings—where early diagnosis can make the biggest difference.
From Research to Real-World Impact: Why MedTech Malta 2025 Matters
Join leaders in diagnostics, AI, and clinical innovation as they gather to explore the practical challenges and breakthroughs driving progress in healthcare. Whether you’re building, investing in, or adopting MedTech solutions, MedTech Malta 2025 offers a focused space to connect with the people moving the field forward. Got questions? Connect with us at [email protected].
